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Abbreviations 12 
AP atmospheric pressure 13 
CID collision-induced dissociation 14 
CT Computed Tomography 15 
DCE Datacube Explorer 16 
DESI desorption electrospray ionization 17 
ECD electron capture dissociation 18 
ETD electron transfer dissociation 19 
ESI electrospray 20 
FAIMS high field asymmetric waveform ion mobility 21 
FFPE formaldehyde-fixed and paraffin-embedded 22 
FTICR Fourier transform ion cyclotron resonance 23 
H&E hematoxylin and eosin 24 
HCD higher-energy collision induced dissociation 25 
IHC immunohistochemistry 26 
IMS ion mobility separation 27 
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IRMPD infrared multiphoton dissociation 28 
ISD in-source decay 29 
LAESI laser ablation electrospray ionization 30 
LA-ICP MSI laser ablation inductively coupled plasma mass spectrometry imaging 31 
LC/ESI-MS/MS liquid chromatography electrospray ionization tandem mass spectrometry 32 
LC-MS liquid chromatography mass spectrometry  33 
LID laser-induced dissociation  34 
MALDI matrix assisted laser desorption ionization 35 
ME-SIMS matrix enhanced secondary ion mass spectrometry 36 
MITICS MALDI imaging team imaging computing system 37 
MS/MS tandem mass spectrometry 38 
MSI mass spectrometry imaging 39 
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scFv single chain variable fragment  43 
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bromide 49 
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Abstract 53 
The recent development of mass spectrometry imaging (MSI) technology allowed to obtain highly 54 
detailed images of the spatial distribution of proteins in tissue at high spatial resolution reaching cell 55 
dimensions, high target specificity and a large dynamic concentration range. This review focusses on 56 
the development of two main MSI principles, targeted and untargeted detection of protein distribution 57 
in tissue samples, with special emphasis on the improvements in analyzed mass range and spatial 58 
resolution over the last 10 years. Untargeted MSI of in situ digested proteins with matrix-assisted 59 
laser desorption ionization is the most widely used approach, but targeted protein MSI technologies 60 
using laser ablation inductively coupled plasma (LA-ICP) and photocleavable mass tag chemical 61 
labeling strategies are gaining momentum. Moreover, this review also provides an overview of the 62 
effect of sample preparation on image quality and the bioinformatic challenge to identify proteins and 63 
quantify their distribution in complex MSI data. 64 
65 
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Introduction 66 
Proteins participate actively in biological events and fulfill a wide range of molecular functions, such 67 
as substrate transport, cellular signaling, catalysis of metabolic reactions, and regulation of DNA 68 
replication and transcription events. Protein expression changes may indicate the presence and 69 
severity of a disease, and can be used to identify disease onset at an early stage, providing better 70 
treatment options for patients. Tissues are particularly important samples in clinical research, because 71 
they contain rich information on morphologic, metabolomic and proteomic changes related to 72 
biological events and disease pathology1,2. The imaging of protein distribution in tissues can provide 73 
new insights into the molecular mechanisms of diseases and the normal function of cells and tissues, 74 
as well as of aging processes. The spatial distribution of proteins in tissue samples provides 75 
information that is complementary to the relative and absolute concentration information obtained 76 
with commonly applied high-throughput molecular profiling omics approaches, such as liquid 77 
chromatography mass spectrometry (LC-MS)-based proteomics and metabolomics. 78 
In order to obtain an image from a complex tissue specimen, several non-invasive imaging approaches 79 
have been developed such as radiography (X-ray, Computed Tomography (CT))3, ultrasonography 80 
(USG)4, positron emission tomography (PET)5 and magnetic resonance imaging (MRI)6 making use 81 
of different measurable physicochemical properties such as emitted/reflected light, particles (e.g. 82 
positrons) and ultrasound. These approaches have contributed significantly to the visualization of 83 
biological processes and many of them are applied routinely in clinical diagnostics. While many 84 
commonly used “non-invasive” (not requiring tissue sampling from patient) imaging technologies, 85 
such as CT and X-ray radiography, and “invasive” (requiring tissue sampling from patients) imaging 86 
technologies, including those based on ultraviolet-visible (UV-VIS) and fluorescence spectroscopy, 87 
are applied to provide high-quality images from tissues, this information cannot always be 88 
straightforwardly translated into an image reflecting the spatial distribution of individual analytes (e.g. 89 
proteins). Immunostaining in combination with optical or fluorescence imaging can provide signals 90 
from specific proteins by visualizing the distribution of antibody-antigen pairs in tissue. However, 91 
images acquired with UV-VIS, fluorescence and radiography7,8 usually provide spatial distribution 92 
for only a limited number of proteins in a single experiment. In addition, most methods require a 93 
priori knowledge of the target molecules, which prevents their use as a hypothesis-free discovery and 94 
hypothesis-generating tool. Some imaging technologies measure the physicochemical properties of 95 
an ensemble of compounds, with spatial localisation in tissue such as nuclear magnetic resonance 96 
spectroscopy, or common UV-VIS microscopy9,10, therefore, only inferring the presence of some 97 
compounds or classes of compounds. In this context, mass spectrometry imaging (MSI) is a powerful 98 
alternative, which circumvents some of these limitations. 99 
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In fact, MSI takes full advantage of the high chemical specificity of mass spectrometry and allow to 100 
quantify the spatial distribution of hundreds of individual molecules in tissues in a single 101 
measurement, without the need for labels or prior knowledge of the analytes. In addition, MSI 102 
technology allows to detect in one experiment multiple compounds which do not ionize well or are 103 
in low abundance, using reagents specifically targeting these compounds. Nowadays, there are several 104 
MSI approaches, which differ in the way that compounds are desorbed into the gas phase and ionized 105 
for sampling into the mass spectrometer, including secondary ion mass spectrometry (SIMS), MALDI 106 
MSI, LA-ICP MSI, desorption electrospray ionization (DESI), rapid evaporative ionization mass 107 
spectrometry (REIMS)11, direct analysis in real time (DART)12 and easy ambient sonic-spray 108 
ionization (EASI)13. Thus, the unique features of MSI to sample compounds directly allows analysis 109 
of many types of (bio)molecules such as proteins, metabolites and drugs, and provides potential for 110 
a wide range of research applications. Examples of these applications include approaches which 111 
provide new insight into normal and disease-related molecular processes14,15,16, enable disease 112 
prognosis and prediction of response to therapy, allow to obtain the distribution of a drug in its intact 113 
form and its metabolites in tissue17–20, or provide classification of tissues based on molecular 114 
information and reveal details of microbiome molecular communication21. 115 
This review focuses on state-of-the-art MSI approaches used to determine protein distribution in 116 
tissues. In details, the manuscript discusses the technical aspects of protein MSI, such as sample 117 
preparation, protein desorption in the gas-phase and ionization, spatial resolution and measured 118 
dynamic concentration range, and presents in detail various MSI approaches for targeted and 119 
untargeted detection of protein distributions in tissue samples. This includes the most commonly used 120 
untargeted protein imaging MSI using MALDI, and other ion generation and sampling approaches 121 
such as LA-ICP MSI, and targeted protein MSI using chemical labeling with photocleavable mass 122 
tags (e.g. Tag-Mass)22–25. One section discusses the data processing and interpretation challenge 123 
related to protein MSI. The review ends with a discussion of the possible future directions of MSI 124 
methodologies for protein distribution analysis in tissue samples. 125 
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1 Main steps of protein distribution analysis in tissue using mass spectrometry 126 
imaging 127 
 128 
Figure 1. An example of mass spectrometry imaging (MSI) using a MALDI interface, which is a commonly used 129 
workflow for peptide/protein distribution analysis in tissue including tissue sectioning and sample preparation (A) and 130 
data acquisition and evaluation (B). 131 
 132 
MSI of protein distribution in tissue samples consists of three main steps: sample preparation, data 133 
acquisition and data (pre-)processing and interpretation (Figure 1). The sample preparation protocols 134 
have a crucial impact on the quality of the MSI process. Sample preparation has the goal to facilitate 135 
the desorption into the gas-phase and the ionisation of proteins or peptides obtained after trypsin 136 
digestion, while keeping protein diffusion to a minimum and maintaining the original spatial 137 
distribution of proteins. These two aims are conflicting, and their balance plays a crucial role in the 138 
quality of the obtained MSI image. The mass spectrometer interface determines the desorption in the 139 
gas-phase, ionization and ion sampling efficiency, the speed of sampling and the area from which the 140 
ions are sampled. The latter property determines the theoretical spatial resolution of the MSI image. 141 
Theoretical spatial resolution can only be reached if sample preparation ensures that local protein 142 
abundance is maintained in the tissue to be imaged. The mass analyzer and acquisition parameters 143 
determine the speed of data acquisition, the type of registered spectra (with or without fragmentation), 144 
the measured dynamic range and the resolution of the acquired mass spectra. Bioinformatics solutions 145 
to pre-process and analyze MSI data form an important part of protein MSI workflows and have the 146 
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goal to interpret the large amount of collected protein distribution information together with other 147 
metadata such as a histology image with anatomical annotation by an expert pathologist26,27. 148 
1.1 Tissue sample preparation 149 
Tissue sample preparation is probably the most critical step to obtain optimal sensitivity, 150 
reproducibility and spatial resolution of the protein distribution in an MSI experiments28,29. 151 
Inappropriate sample preparation leading to protein degradation, signal interference by non-target 152 
chemical species, alteration of the original protein distribution, or low ion sampling efficiency due to 153 
insulating properties of tissue have a negative effect on the quality of the acquired MSI data. Normally, 154 
tissue sample preparation involves organ harvesting and tissue sectioning (Figure 1). In order to avoid 155 
delocalization and degradation of proteins, it is essential to handle tissues correctly starting with the 156 
surgical removal process. After removal of the tissue from the body, tissue samples should be 157 
immediately snap-frozen in 2-methyl-butane (isopentane) and stored at -80 °C until use. For MSI of 158 
proteins, fresh frozen tissue is preferred over alcohol-preserved, or formaldehyde-fixated and 159 
paraffin-embedded (FFPE) tissue sections, because of the covalent crosslinking of proteins in FFPE 160 
sections or precipitated proteins in alcohol-preserved sections, although recently the antigen retrieval 161 
strategy has been suggested to overcome the protein crosslinks in FFPE sections30,31. In all cases, 162 
tissue sections with a thickness of approximately 10 μm are prepared with a microcryotome. It is 163 
important to place the frozen tissue sections on sample plates or conductive glass slides without 164 
scratches, rips or tears. Once the section (at this point still frozen) is in position, it is thaw-mounted 165 
by warming the bottom of the sample plate for macroscopic drying of the section which usually takes 166 
20-30 seconds. Freeze-drying of tissue sections is an often performed operation, however many 167 
researchers omit this step from their tissue preparation pipelines without issue32. The sample plate 168 
and tissue section are quickly warmed together, resulting in no loss of water-soluble proteins nor 169 
translocation of the proteins due to diffusion in the liquid state33. 170 
Biological tissues contain numerous chemical species over a wide range of concentrations, and more 171 
abundant and/or easier ionizable species such as lipids can suppress the detection of less abundant 172 
species due to charge competition of compounds during ionization. For instance, salts and lipids34 173 
will interfere with MALDI MSI of proteins or peptides. To partially overcome these problems, tissue-174 
washing procedures have been introduced prior to matrix deposition when using the MALDI MSI 175 
method. These washing protocols vary greatly depending on the target analytes. Ideally, all of the 176 
unwanted chemical species should be removed from the tissue while maintaining tissue morphology 177 
and not disturbing the original spatial distribution of soluble proteins. Assessment of all tissue-178 
washing steps is necessary since each one may lead to some degree of disruption of the original spatial 179 
distribution of analytes in the tissue. 180 
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Matrix application is required for some of the approaches such as MALDI MSI or matrix enhanced 181 
secondary ion mass spectrometry (ME-SIMS) MSI. The most widely used technique for MSI is 182 
MALDI, for which the reproducibility of the ionization process is still a challenge and the MS 183 
acquisition parameters are difficult to optimize. Matrices such as 3,5-dimethoxy-4-hydroxycinnamic 184 
acid (sinapinic acid) and α-cyano-4-hydroxycinnamic acid are generally used to promote ionization 185 
and prevent degradation of target compounds by the probe beam (laser) energy. Generally, ion signal 186 
intensities in MALDI-MS are strongly influenced by the choice of matrix compound and the matrix 187 
preparation and deposition procedure, which determines the size distribution of the matrix crystals. 188 
Matrix crystal size is the most important parameter, which influences the ionization efficiency and 189 
reproducibility of desorption in the gas-phase of compounds. The goal of the procedure is to obtain a 190 
homogeneous distribution and uniformly small crystal sizes of matrix for optimal performance35. 191 
Several matrix application and drying cycles can be performed until an optimal matrix thickness with 192 
high quality and homogeneity is achieved. There are several methods by which a homogeneous matrix 193 
layer can be applied, such as spraying, solvent free dusting or coating by sublimation36, and manual 194 
or robotic spotting37,38. Manual spraying is an often used, simple approach for matrix application 195 
which works well in the hands of an experienced operator, without requiring sophisticated 196 
instrumentation. However, automatic deposition provides a more homogenous matrix layer and 197 
improved reproducibility enhancing the imaging performance. The review by Goodwin on commonly 198 
used matrix and matrix applications approaches for MSI provides more details on this topic29. 199 
In MALDI MSI, proteins are measured with two approaches: either in their intact form, where smaller 200 
proteins are easier to measure than large proteins, or after digestion using a protease such as trypsin, 201 
which has the advantage that there is no limit with respect to protein size. Mass spectrometers with 202 
higher mass resolution allow to achieve better mass accuracy which improves identification of 203 
peptides and proteins. Moreover, since peptides are easier to detect and identify, this facilitates 204 
subsequent identification of proteins and their post-translational modifications. These two approaches 205 
are discussed in detail in sections 2.1.3 and 2.1.4. 206 
1.2 Desorption and ionization of peptides and proteins from tissue 207 
The choice of desorption (extraction into the gas-phase) and ionization technique has an important 208 
influence on the spatial resolution of the obtained MSI image and on the detected compound profile 209 
(Figure 2). SIMS is using high-energy primary ion beams of ionized noble gas, oxygen, fullerene or 210 
SF6, to generate and to sputter secondary ions from sample surface. SIMS was introduced to MSI in 211 
the 1960s and was developed to detect atoms or small fragments of vitamins, pharmaceuticals, lipids 212 
and peptides in tissue and cells39–41. SIMS was applied to obtain information on elemental, isotopic 213 
and molecular composition of the upper atomic layers of the scanned sample42,43. It has the primary 214 
9 
advantage of achieving a high spatial resolution (< 100 nm or even ≤ 20 nm), which cannot be 215 
achieved with MALDI, LDI or DESI interfaces44,45,54–57,46–53. However, SIMS suffers from severe in-216 
source fragmentation of biomolecules due to excessively hard ionization, which results in impaired 217 
identification of target analytes. The lower sensitivity of SIMS-MSI in comparison to MALDI MSI 218 
in detecting peptides and proteins was reported in several studies58. 219 
DESI is an ambient ionization technique developed by Zoltán Takáts, Graham Cooks and their 220 
coworkers in 2004 at Purdue University59,60. In this method, a fast, nebulized electrospray gas jet 221 
transports charged microdroplets of an eluent to impact the surface of the sample and to carry away 222 
ionized molecules. The approach requires no or limited sample preparation effort and allows simple 223 
MSI under ambient conditions preventing change in tissue slice shape. Furthermore, DESI is a spray-224 
based soft ionization technique with an average internal energy deposition of ~2 eV, which is similar 225 
to the internal energy deposition of electrospray (ESI)61. Thus, DESI yields minimal fragmentation 226 
of large molecules compared to the excessive fragmentation of SIMS62 and avoids interference with 227 
the matrix compounds, such as observed in MALDI. DESI MSI and other variants, such as nano-228 
DESI, have been used for imaging compounds in the low mass region below 1000 Da with a high 229 
spatial resolution (approximately 10 μm), as shown for metabolites in leaf tissues or drugs (e.g. 230 
clozapine) distribution in animal tissue sections and microbiome sampling18,63–67. The spot size and 231 
spatial resolution in (nano)-DESI-MSI – amongst other parameters – depend on the capillary diameter, 232 
angle of spray incidence and the tip-to-surface distance, which can be difficult to optimize68. (nano)-233 
DESI MSI suffers from the limitation of a much lower spatial resolution compared to SIMS and 234 
MALDI, which is for (nano)-DESI typically around 100 μm or upwards in imaging of peptides or 235 
proteins69–72. Recently, Garza et al. presented a DESI-high field asymmetric waveform ion mobility 236 
(FAIMS) device for protein mass spectrometry imaging and reported to simultaneously detect lipids 237 
and intact protein forms in mouse kidney, mouse brain, and human ovarian and breast tissue samples73. 238 
Another ambient ionization method is laser ablation electrospray ionization (LAESI)74,75, which was 239 
introduced by Vertes et al. in 2007 and combines laser ablation with a mid-infrared laser and 240 
electrospray ionization, where the latter serves to ionize the laser ablated compounds74. LAESI does 241 
not require complex sample preparation for MSI of peptides or proteins. However, it also suffers from 242 
low lateral resolution, which does not allow detailed (sub)cellular imaging. 243 
It is necessary to find a technology to overcome all of the above-mentioned issues that can be used 244 
for imaging protein distributions in tissue samples. In this context, currently three MSI approaches 245 
are used: (1) untargeted MSI of proteins using MALDI, (2) targeted MSI of proteins based on 246 
detecting metals ions in their active sites or structural domains or metal ions coupled to antibodies 247 
using LA-ICP MSI such as used in mass cytometry, and (3) targeted MSI of proteins using chemical 248 
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labeling, where the chemical label consists of a protein targeting affinity moiety (antibody, affirmers, 249 
activity probes) coupled with photocleavable (PC) mass tags, where mass tag labels are released and 250 
measured with MALDI or LDI. 251 
MALDI was the first MS-based method for imaging intact proteins in a human glioma76 and is 252 
currently by far the most commonly used untargeted MSI approach for imaging protein 253 
distribution77,78. The first application of MALDI MSI in mapping peptides and proteins in biological 254 
samples was developed by the groups of Bernard Spengler (1994)79 and Richard Caprioli (1997)80. 255 
MALDI MSI has since become a mature technology to determine the distribution of proteins over a 256 
large mass range from hundreds of Da to beyond 100 kDa with little or no fragmentation of the 257 
original protein81,82,83–85. During the last decade, MALDI imaging has been further improved, with 258 
respect to detection sensitivity and spatial resolution86,87–91. Current methods can reach a spatial 259 
resolution of 10-20 μm84,92, a value that is limited by the crystal size distribution of the matrix, and 260 
therefore does not reach the typical spatial resolution of 100-250 nm of (nano)SIMS. In a typical 261 
MALDI MSI interface, ions are formed under vacuum, which constraints the choice of matrix, and 262 
may change tissue section morphology. To overcome these problems, atmospheric pressure MALDI 263 
(AP-MALDI) ion sources have been developed for MSI applications, where ions are generated at 264 
ambient conditions and transferred into the vacuum of the mass analyzer using methods similar to 265 
those developed for introduction of ions generated via ESI. AP-MALDI MSI using IR or UV lasers 266 
provides high spatial resolution (1.4 μm) in mapping small biomolecules, such as metabolites, lipids, 267 
peptides and carbohydrates, but has so far not been applied for protein MSI93–97. In addition, lower 268 
sensitivities are observed with AP-MALDI than with vacuum MALDI sources in analyzing plant 269 
metabolites98. 270 
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 271 
Figure 2. The main characteristics of desorption (extraction in the gas-phase) and ionization interfaces used for mass spectrometry imaging. Abbreviations: LOD: Limit of detection; 272 
AP: Atmosphere pressure; IP: Intermediate pressure. UHV: Ultra-high vacuum. *Static SIMS MSI detection of intact molecules above 1,500 Da from biological samples is rarely 273 
reported owing to source-induced fragmentation and high LOD for peptides and proteins. LAESI combining DESI and LA for desorption-ionisation was not included in the figure. 274 
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Other laser irradiation-based desorption/ionization MSI interfaces have been used in protein MSI 275 
besides those mentioned above, such as matrix-assisted laser desorption electrospray ionization 276 
(MALDESI)99, and infrared laser desorption electrospray ionization (IR-LDESI)100. LA-ICP MSI is 277 
another popular approach used for imaging trace elements (e.g. metals and metalloids) in biological 278 
materials with a spatial resolution ranging from 200 μm down to 10 μm for a wide range of 279 
applications, among them visualization of metal-containing proteins101–103. 280 
1.3 Data processing and analysis 281 
1.3.1 Spatial resolution in MSI 282 
Spatial resolution is a key parameter to assess the performance of MSI. Spatial resolution is defined 283 
in the imaging field as the ability to distinguish two data points with different information content 284 
separated in units of distance such as mm or μm. Current MSI technology is able to provide data at 285 
low and submicron resolution, however, the spatial resolutions of 10-50 nm104 achieved by super-286 
resolution imaging is still not achievable. The term spatial resolution is used in multiple contexts, 287 
which often leads to confusion. The concept and definition of spatial resolution in the context of MSI 288 
is provided here. In general, a tissue is a three-dimensional (3D) compartment, whose MS imaging 289 
also provides 3D data, with three coordinate dimensions in tissue and one mass spectrum for each 290 
spatial coordinate. A general imaging approach such as MRI, PET or CT collects information on the 291 
entire 3D volume of data and in this context two types of resolution are defined: in the axial and the 292 
lateral dimension. Axial (longitudinal, azimuthal, range, radial, and depth105) resolution is defined in 293 
parallel to the probe beam of electrons, ions, or photons and defines the ability to distinguish 294 
structures at various depths of the sample with respect to the tissue surface106. 295 
Conversely, lateral resolution is defined perpendicular to the probe beam and defines the ability to 296 
distinguish structures which lie close to each other side by side, as individual objects. Lateral 297 
resolution is affected by the width of the beam, the difference between two adjacent coordinates (step 298 
size of sampling) at the tissue surface, but also depends on the depth of imaging i.e. the distance that 299 
the beam penetrates the tissue surface, since compounds are sampled from a tissue volume reached 300 
effectively by the sampling beam. Wider beams typically scatter in the tissue section and therefore, 301 
lateral resolution is improved by using narrower beams and beams that do not penetrate the tissue to 302 
great depths107. MSI is a surface scanning technology, with a low penetration depth into the sample, 303 
which is generally applied to a tissue section of a few µm thickness. Therefore, lateral spatial 304 
resolution in the plane of the tissue section is the important resolution parameter and this is the 305 
definition of spatial resolution used in this review. MSI techniques which acquire data from 3D 306 
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samples achieve this by merging mass spectrometry ion intensity data from adjacent tissue 307 
sections108–112. 308 
Spot size, pixel size and step size are important terms to describe the lateral resolution obtained in 309 
MSI. Spot size refers to the focus area of the probe beam (laser pulse, ion beam, etc.)113, which has 310 
two definitions; one is based on a Gaussian distribution model of the beam intensity, or irradiance, 311 
across its standard deviation, while the second definition expresses the width of the beam at half-312 
intensity114,115. Pixel size refers to the lateral binning (summing up intensity between a predefined set 313 
of borders) of 2D data into digital image elements and the step size refers to the raster of the sampling 314 
stage or beam deflections57. Step sizes smaller than the spot size were found to generate lower quality 315 
images when sampling with a laser which does not ablate all ionizable compounds from one spot. In 316 
this case, the tissue area is sampled with high overlap in adjacent sampling positions and sampling 317 
from the subsequent spot will result in some signal from compounds of the previous spot position. 318 
This is called oversampling. When the sampling area is completely ablated at each position without 319 
oversampling, the overlapping position will not be cross contaminated and leads to a clear image. In 320 
this case the resolution of the image is determined by the step size, since for each spot the sampled 321 
ions originate from the non-overlapping and non-ablated sample area. For this situation the lateral 322 
resolution is not limited by the diameter of the probe beam, but the intensity of the sample compound 323 
will be lower due to the lower amount of available material in the non-ablated sample area116,117. 324 
1.3.2 Pre-processing and visualization of large MSI data 325 
The data pre-processing, visualisation and interpretation depends on the dimensionality of the MSI 326 
data. Tissue specimen has 3 dimensions (3D), from which a planar 2-dimensional (2D) tissue section 327 
with defined thickness (generally 5-10 μm) is used for MSI. Orientation of the tissue section used for 328 
MSI should be provided by sampling using an anatomical orientation description118. If multiple 329 
adjacent tissue sections are analyzed then volumetric MSI data is acquired119. The dimensionality of 330 
the MSI data is generally reflected as the spatial dimensions of the analysed tissue, thus it can be 2D 331 
or 3D. MSI data obtained from a single tissue section is multidimensional with two spatial, one 332 
separation (m/z) dimension and one quantitative readout (ion intensity). The two spatial dimensions 333 
are in the plane of the analysed tissue section and the separation dimension consist of the mass-to-334 
charge (m/z) separation. The ion intensity is the quantitative readout, which is used for quantification 335 
of the measured compounds. 336 
“Pseudo” MSI data can be obtained by taking individual samples at different parts on an organ, the 337 
full body or body surface and analyzing the samples with LC-MS or MALDI time-of-flight (TOF). 338 
Mapping the measured data to the original sample location enables coarse mapping of compound 339 
14 
distribution in the analyzed samples, as shown in a study measuring metabolites, peptides and proteins 340 
in samples taken from skins of volunteers by Bouslimani et al120. 341 
The size of the MSI data collected on large tissue sections at high spatial resolution is large and ranges 342 
typically from 1 to 100 GB and in extreme cases can reach 1 TB such as for 3D FTICR data, but 343 
smaller data sets of a few to hundreds of MB targeting small tissue areas with low spatial resolution 344 
is collected routinely. There are many ways to pre-process, analyze and evaluate the large amount of 345 
MSI data, and the main aims are to obtain a better understanding of the underlying molecular 346 
mechanisms of biological events such as: (1) to determine the spatial distribution of compounds and 347 
how this correlates with the anatomic morphology and cellular composition of the tissue, (2) to 348 
determine how the spatial distribution of a particular compound correlates with those of the other 349 
compounds. In the data interpretation process, visualization plays an important role, which is 350 
challenging for the large amount of MSI data, but large data sets represent a challenge for pre-351 
processing as well. In order to reduce the volume of data, many data pre-processing pipelines use data 352 
reduction techniques such as centroiding, noise reduction, intensity filtering and baseline removal, 353 
creating images for features (isotopes) detected in a minimum number of spectra or filtering out ion 354 
images that have low information content121,122. 355 
Suits et al.123,124 presented an approach which does not use any data reduction and allows to process 356 
large volume profile MSI dataset as it was collected. This is achieved by using three different types 357 
of indexed data structures of the same MSI data to allow interactive data interpretation by the users 358 
without loss of information (Figure 3): (1) one representation contains sliced MSI data in the m/z 359 
dimension with user defined thickness for fast visualization of MSI ion images, and enables 360 
correlation queries between slices to find compounds that show spatial correlation with each other or 361 
with an anatomical location, (2) representation of all MSI data in triplets of m/z, intensity and pixel 362 
index. In this data, triplets are sorted and indexed according to m/z values, which serves to recalculate 363 
a slice in the m/z dimension quickly with user defined thickness and m/z limits using a graphical user 364 
interface, and (3) indexed storage of all MS spectra of each image pixel serving to quickly get MS 365 
spectra for a particular tissue location. 366 
The next level of data analysis is based on clustering similar mass spectra to determine how the spatial 367 
distribution of the mass spectra clusters correlates to anatomic structures, a process called 368 
segmentation. Another bioinformatics task is the alignment of the histology image with MSI data, 369 
which transfers identified anatomical regions in the histology image to the MSI data and enables 370 
identification of compounds in the identified anatomical region. This procedure is called the image 371 
registration process and performs 2D alignment of the histology image to e.g. a specific m/z slice or 372 
to the total ion current image (the sum of all ion intensities collected for one pixel) of MSI data125. 373 
15 
Visualization of 2D MSI data obtained from one tissue slice is already challenging since one pixel is 374 
described with four values (x and y coordinates, m/z value and intensity) and the most common 375 
approach is to provide 2D images of single (normal image showing intensity as a color map) or 376 
multiple (separate red, blue and green color maps combined with intensity dependent transparency 377 
for 3 different slices) m/z slices. Visualization of ion intensity for a particular m/z range in 3D MSI 378 
data obtained from a volumetric sample or visualization of multiple m/z slices in 2D MSI can be 379 
performed with volumetric rendering frequently used in 3D computer graphics. Volumetric rendering 380 
is a 3D visualization method for 4D data where the color and the transparency of one pixel is set 381 
according to its intensity values (pixels with lower intensity are more transparent than pixels with 382 
higher intensity)109. 383 
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 384 
Figure 3. Data processing workflow, which allows analysing of all signals collected in an MSI experiment using an Orbitrap Velos instrument equipped with a MALDI interface 385 
interactively without information loss. Reprinted with permission from Suits et al123. Copyright (2013) American Chemical Society. 386 
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Identification of the detected peptides and proteins by MSI is still challenging, for instance due to the 387 
presence of isobaric compounds, poor fragmentation of large proteins, the presence of metabolites, 388 
adduct formation and the presence of non-tryptic peaks when local trypsin digestion is performed on 389 
the tissue section. Improvement of mass spectrometer sensitivity will allow detection of lower 390 
abundant proteins, but may actually exacerbate the identification challenge by increasing spectrum 391 
complexity. With a tandem mass analyzer, ions of interest can be specifically targeted for 392 
fragmentation, to facilitate their identification. However, tandem mass spectrometry (MS/MS) 393 
spectra of sufficient quality can only be obtained for ions with high intensity signals. An open non-394 
reviewed database, the MSiMass list (https://ms-imaging.org/wp/msi-mass-list), helps users to assign 395 
identities to peaks submitted to MS/MS fragmentation observed in MALDI MSI experiments. This 396 
database is the result of a community effort without a formal review panel and therefore information 397 
in this database should be considered with care. In this concept, authors can freely enter data and can 398 
comment on existing entries. Its ability to provide high quality data and identification is currently 399 
under evaluation126. In this section we have mentioned only the most important aspects and challenges 400 
of MSI data processing and the reader is referred to a recent detailed review by Alexandrov on this 401 
topic127. 402 
MSI data is acquired with a wide range of MS systems and many software tools are available to 403 
process MSI data. For MSI data processing, imzML128,129 is the accepted open standard format, which 404 
is supported by the Proteomics Standards Initiative of the Human Proteome Organisation (HUPO-405 
PSI)130, and has become widely used for the flexible exchange and processing of MSI data between 406 
different instruments and data analysis software. High-resolution molecular profiles of tissue 407 
collected from MSI experiments often have data files of sizes of several tens to hundreds of gigabytes 408 
requiring powerful visualization software, such as the Biomap (Novartis, Basel, Switzerland, 409 
www.maldi-msi.org) image processing application, the MALDI Imaging Team Imaging Computing 410 
System (MITICS)131 and the Datacube Explorer (DCE, available at the www.imzml.org) to explore 411 
imaging mass spectrometry data sets132. Recently, high-quality 3D MALDI and DESI benchmark 412 
MSI datasets in imzML format were made available for software evaluation purposes133. 413 
2 Untargeted mass spectrometry imaging of proteins 414 
This section discusses MSI strategies for hypothesis-free untargeted analysis of protein distribution 415 
in tissue and presents the technological limitations and current challenges, illustrated with example 416 
applications. Untargeted analysis of protein distribution requires the collection of ion intensity signals 417 
specific to proteins and linking accurate identification to these signals. In untargeted MSI, proteins 418 
can be identified with two approaches. In the first approach the proteins are digested in situ by 419 
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application of a protease (typically trypsin) in isolated spots, and the proteins in these spots are 420 
cleaved into peptides. These peptides are then ionized, sampled into the mass spectrometer and 421 
analyzed intact or following fragmentation using conventional MS/MS fragmentation methods such 422 
as collision induced (CID) or electron transfer dissociation (ETD). The application of droplets limits 423 
the spatial resolution of this approach. The second approach uses ionize, sample into the mass 424 
spectrometer and analyze intact proteoforms, which can be combined with fragmentation methods 425 
such as higher-energy collision induced dissociation (HCD) and ETD that can be directly applied to 426 
intact proteins extracted from tissue and submitted to purification134–136. The first strategy does not 427 
provide information on the entire protein sequence, and the detected peptides in many cases do not 428 
allow differentiation between protein isoforms or partially degraded proteins in the absence of 429 
additional information (e.g. the mass of the intact protein). Top-down fragmentation of intact protein 430 
provides more complete information on the entire protein sequence and allows better discrimination 431 
between isoforms, but requires clean and extracted proteins and cannot be applied directly in an MSI 432 
setting. The advantage of the first approach is that it can be applied to determine the distribution of 433 
post-translational modifications of specific residues in proteins directly from tissue137. 434 
2.1 Untargeted MALDI MSI of intact proteins in tissue 435 
2.1.1 Extending the mass range for intact protein MALDI MSI 436 
The matrix deposition method has a critical impact on the mass range of intact protein MSI. 437 
Leinweber et al. developed a sandwich matrix deposition protocol, which includes application of 438 
different solvents and detergents for MALDI MSI of proteins in tissue sections, extending the mass 439 
range to 25-50 kDa and increasing the number of detected intact proteins. This protocol uses two 440 
layers of matrix, one below and one on top of the tissue section, and has been employed for MSI of 441 
proteins in kidney, heart, lung and brain tissue sections of different rodent species138. Grey et al. 442 
introduced a tissue preparation procedure, which includes extensive washing with water to remove 443 
highly abundant water-soluble proteins, and automated spotting of matrix solution using a high 444 
percentage of organic (acetonitrile) solvent. This protocol allowed to measure membrane proteins up 445 
to 28 kDa in bovine lens, human lens, and rabbit retina by MALDI MSI, but at moderate spatial 446 
resolution of 100-200 µm due to application of matrix spotting139. Franck et al. enhanced the 447 
solubilization of large proteins using hexafluoroisopropanol (1,1,1,3,3,3-hexafluoro-2-propanol) and 448 
2,2,2-trifluoroethanol during sample preparation and achieved MSI of proteins between 30 and 70 449 
kDa directly from tissue140. Mainini et al. investigated ferulic acid as matrix on different tissues 450 
deposited with an automated matrix deposition device, ImagePrep (Bruker Daltonics, Bremen, 451 
Germany), which performs matrix deposition by spraying sequences and allowed the detection of 452 
proteins up to 135 kDa141. 453 
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The shortcoming of widely-used mass spectrometers is the inefficient transmission and fragmentation 454 
of large proteins138,140–144, particularly the low transmission efficiency of the latter. Recent 455 
development of mass spectrometers has enabled the implementation of large protein analysis even 456 
under native conditions by enhancing the ion transmission of intact proteins up to one megadalton145. 457 
These developments have allowed to expand the mass range within which intact proteins can be 458 
analyzed and will certainly contribute to generate more informative MSI data. 459 
Another improvement of MSI of intact proteins was achieved by van Remoortere et al., who used a 460 
high mass HM1 TOF detector (CovalX, Zurich, Switzerland) to improve the sensitivity of MALDI 461 
MSI of intact proteins up to 70 kDa146. Compared with traditional micro-channel plate detectors, this 462 
instrument has a much larger charge capacity and is therefore less prone to detector saturation. 463 
Another novel method in MALDI MSI was described by Jungmann et al., who used a parallel, active 464 
pixel TOF detector for MSI of ubiquitin oligomers reaching a molecular mass of 78 kDa147. 465 
Although these methods demonstrate encouraging results for imaging proteins of increasing mass, 466 
each of these protocols has some drawbacks that are usually associated with low reproducibility, 467 
including: ion suppression effects148, low ion yield (it has been estimated that only 1 molecule ionizes 468 
out of 1000 desorbed proteins149–151), the need for a special non-commercially available mass 469 
analyzer146, a limitation to detect membrane proteins139, the requirement of complex and laborious 470 
experimental protocols138 and time-consuming, as well as extensive sample preparation140. 471 
2.1.2 Spatial resolution improvement of MALDI MSI for intact proteins 472 
A number of methods were developed to implement the spatial resolution of MALDI MSI of proteins 473 
from tissue samples. These methods focused on improving the sample preparation protocol, reducing 474 
the laser beam spot size, and improving the ion sampling and transmission parts of the mass 475 
spectrometer. As mentioned in section 2.1.1, tissue sample preparation is the most important factor 476 
to achieve both high sensitivity and high spatial resolution in MALDI MSI. McDonnell et al. 477 
performed an extensive comparison of five tissue washing protocols using human arterial tissue 478 
samples, and assessed the methods in terms of the information content (e.g. number of detected peaks, 479 
quality of morphological structures) as well as their suitability for analyzing tissue containing small 480 
but distinct regions. In this work, they demonstrated an optimized tissue washing protocol using 70% 481 
and 90% isopropanol for imaging proteins that are specific to the intimas and media layers of 482 
atherosclerotic arterial tissues at a high spatial resolution of 30 μm152. With an appropriate laser spot 483 
profile (flat-top) and diameter (10-20 μm) and a matrix application method (spraying matrix with the 484 
Bruker ImagePrep device) that precludes analyte delocalization and maintains the original lateral 485 
spatial distribution of proteins, the group of Pineau reported a MALDI MSI of proteins in the 10 kDa 486 
range in rat testis tissue at 20 μm lateral resolution136. Caprioli’s group implemented a matrix 487 
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sublimation/recrystallization process, which provides a more homogeneous distribution of the matrix 488 
resulting in more sensitive detection of large proteins using MALDI MSI with a spatial resolution as 489 
low as 10 μm84. Additionally, for targeted analysis, histology-directed imaging was performed using 490 
this protocol, where MSI analysis and hematoxylin and eosin (H&E) staining were performed on the 491 
same tissue section which was previously used for MSI. Integrating H&E staining with MSI data 492 
acquired on the same tissue section allows to transfer anatomical annotation from H&E staining to 493 
MSI data and allows to identify protein signals which correlate spatially with anatomical features. In 494 
another study, Deutskens et al. applied a robotic spray apparatus for matrix application, and 495 
performed MALDI MSI on a tissue section followed by elimination of the matrix by washing and 496 
subsequent histology staining and microscopic examination of the same tissue section. This matrix 497 
application protocol has two steps (one dry matrix coating and one hydration/recrystalisation), which 498 
separates the processes of matrix coating from analyte extraction and provides a highly reproducible 499 
homogenous matrix layer. A key advantage of this protocol is that it limits the delocalization of 500 
proteins and enables imaging at a relatively high spatial resolution of 35 µm153. 501 
The spatial resolution achievable with MALDI is ultimately restricted by the size of the laser spot154. 502 
While it is possible to image with a spatial resolution less than the diameter of the laser beam by 503 
oversampling (i.e. with a laser spot size of 60 μm, one could raster with 20 μm steps) to effectively 504 
achieve 20 μm spatial resolution116, it is important to completely ablate the prior spot before moving 505 
the laser beam to the next position to reduce crosstalk between pixels. To minimize the laser spot size, 506 
the group of Caprioli et al. developed a new source for MSI with a transmission geometry that allows 507 
the laser beam to irradiate the backside of the sample and the separation of ion and laser optics 508 
resulting in a laser spot size close to the wavelength of the applied laser, thereby allowing MSI at 509 
higher spatial resolution. This method produced high-quality images of intact insulin in the cytoplasm 510 
at sub-cellular resolution in mouse cerebellum tissue155. With appropriate sample preparation and 511 
using 2,5-dihydroxyacetophenone as matrix, the transmission geometry principle was able to achieve 512 
a 1 μm laser spot diameter on target with a minimal raster step size of 2.5 μm. This approach allowed 513 
to produce mass spectrometry images of proteins acquired in a step raster mode at 5 pixels/s and in a 514 
continuous raster mode at 40 pixels/s156, which  is much faster than the 0.5-2 pixel/s acquisition of 515 
common QTOF and Orbitrap instruments. Increasing acquisition speed has the advantage that data is 516 
acquired within a reasonable time frame, which prevents molecular alteration of tissue in time from 517 
the beginning to the end of the MSI process. Zavalin et al.157 developed a “laser beam filtration” 518 
approach, using lenses and a 25 µm ceramic spatial filter (pinhole) to remove the satellite secondary 519 
laser beam energy maxima resulting in a well-defined 5 μm diameter laser spot. The images generated 520 
from a mouse cerebellum showed clearly distinguishable cellular forms such as the Purkinje layer, 521 
dendrites, and axon fibers. Spengler’s group introduced a Scanning Microprobe Matrix Assisted 522 
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Laser Desorption/Ionization (SMALDI)-MSI method, which features the possibility to investigate 523 
and visualize the spatial distribution of analytes including peptides such as bradykinin and angiotensin 524 
II in samples with sub-cellular resolution (0.5-10 μm) in pine tree roots107,158. 525 
Spatial resolution MSI of proteins from tissue sections can also be improved with specific sample 526 
preparation techniques or with dedicated data processing. Caprioli et al. have developed an approach 527 
to image proteins by blotting the tissue sections on a specially prepared target containing an adsorbent 528 
material80. Peptides and small proteins bind to the C18 material and create a positive imprint of the 529 
tissue, which can then be imaged by the mass spectrometer. The imprinted tissue material prevents 530 
any further delocalization of proteins and enables washing away interfering compounds such as lipids 531 
and salts. This approach has been applied to map proteins from the rat pituitary gland with a spatial 532 
resolution of ~25 µm. Integration of a coaxial laser illumination ion source into a MALDI-TOF-MS 533 
instrument allowed visualization of proteins of a molecular mass up to 27 kDa using this approach. 534 
In another study, two highly expressed secretory epididymal proteins in a mouse caudal epididymis 535 
tissue section were visualized, with a spatial resolution below 10 µm92. 536 
Low spatial resolution MSI data can be combined with high-resolution spatial microscopic images 537 
using multivariate regression called image fusion approach. Image fusion enables to predict 538 
distribution of MSI data at the spatial resolution of the H&E image. The resulting images combine 539 
the advantages of both technologies, enabling prediction of a molecular distribution both at high 540 
spatial resolution and maintaining the high chemical specificity of MSI data. For example, an ion 541 
image of m/z 778.5 (identified as a lipid) measured in mouse brain at 100 µm spatial resolution, can 542 
be extrapolated for 10 µm spatial resolution using fusion with H&E microscopy image measured 543 
from the same tissue sample at 10 µm resolution. Another example describes the prediction accuracy 544 
of an ion image with m/z 10,516 Da corresponding to an unidentified protein measured in a mouse 545 
brain section at 100 µm resolution and fused with an H&E microscopic image resulting in a predicted 546 
image at 5 µm resolution. This approach has been successfully applied for various tissue types, target 547 
molecules and histological staining protocols at different resolution scales. In addition, this approach 548 
can generate ion image predictions using microscopic images at the nanometer range, below the 549 
resolution achievable with current MALDI MSI instrumentation159. However, it should be noted that 550 
the image fusion approach is a statistical procedure predicting distribution at higher spatial resolution 551 
than the actually acquired MSI data. Therefore, thorough assessment of the prediction accuracy 552 
should be applied for each specific location and m/z slice. 553 
A study from Spraggings et al.160 presents an ultra-high speed MALDI-TOF MS, which provides 554 
image acquisition rates >25 pixels/s with high spatial resolution of 30 (full tissue section) and 10 µm 555 
(only selected tissue areas due to time required to collect the data) and a high mass resolution MALDI 556 
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Fourier transform ion cyclotron resonance (FTICR) MS operated with 100 µm spatial resolution. 557 
These novel instruments improve protein image acquisition rates by a factor of 10, can provide 558 
MALDI MSI data at 10 μm spatial resolution with good sensitivity, and isotopically resolve proteins 559 
up to 20 kDa. The data from these two instruments on the same tissue section could be combined e.g. 560 
with interpolation similar to the image fusion approaches resulting in high spatial resolution and high 561 
mass accuracy MSI data. 562 
2.1.3 Identification of intact proteins in MSI 563 
Intact proteins can be fragmented in the gas phase outside or inside the mass spectrometer through 564 
various mechanisms161, such as MALDI in-source decay (ISD), collision-induced dissociation (CID), 565 
infrared multiphoton dissociation (IRMPD), electron capture dissociation (ECD), ETD, ultraviolet 566 
photodissociation (UVPD) and laser-induced dissociation (LID). Among these, MALDI ISD162–164, 567 
where the fragmentation occurs in the MALDI ion source is the most widely used approach80,76,165. 568 
ISD has proven to be an efficient method for the N- and C-terminal sequencing of proteins in tissue 569 
sections. In ISD, proteins are cleaved at the N-Cα bond of the peptide backbone at high laser fluence 570 
(radiant exposure expressing the amount of energy received per unit of surface area) in the hot 571 
MALDI plume, giving principally c-and z-type protein fragments166. As early as 2001, Chaurand et 572 
al. applied ISD-MSI in the characterization of spermine-binding protein (SBP) in mouse prostate 573 
lobes with respect to sequence variants and PTMs and the localization of this protein167. The main 574 
advantage of ISD is that there is no mass limitation since fragmentation occurs prior to ion 575 
acceleration. However, ISD suffers from the major drawback of lack of precursor ion selection, which 576 
leads to a complicated mass spectrum if more than one protein is present at the laser shot position, 577 
which is generally the case in MSI of tissue section. In addition, many c- or z-fragment ions below 578 
1000 Da are often difficult to assign due to the presence of matrix adduct peaks, making the 579 
identification of the sequence part close to the protein termini challenging. ISD-MSI require multiple  580 
laser shots in the same spot ablating all available proteins to gain the highest signal, which is a time-581 
consuming task. 582 
To circumvent this issue, a “pseudo-MS3” approach, also known as “T3-sequencing”, has been 583 
developed to improve MALDI-ISD in proteins168,169. In this approach, the fragments produced by 584 
ISD are further isolated and fragmented with a classical tandem MS/MS approach in QTOF or 585 
MALDI-TOF/TOF instruments. The T3-sequencing method with specific MALDI matrices, such as 586 
2,5-dihydroxybenzoic acid or 1,5-diaminonaphthalene, has been applied to identify proteins such as 587 
myelin basic protein and crystallins in the tissue slices of mouse brain and porcine eye lens 588 
respectively163. The efficacy of MALDI-ISD-MSI to simultaneously identify the protein and 589 
determine its localization has been demonstrated in another study using tissue sections of porcine eye 590 
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lens. In this study a new bioinformatics pipeline was presented for processing MALDI-ISD-MSI data 591 
to identify proteins based on spectra containing high numbers of correlated fragments that are likely 592 
to be part of the same protein. This approach allows to determine the lateral spatial distribution of 593 
identified proteins as well170. Pauw and coworkers recently presented a high-resolution MALDI-ISD- 594 
FTICR method to identify a set of selected protein markers on histological slices simultaneously with 595 
minimal sample pretreatment171. In this method, known protein markers are spotted next to the tissue 596 
of interest and the whole MALDI plate is coated with 1,5-diaminonaphthalene matrix. The latter 597 
promotes MALDI ISD, providing large amino acid sequence tags. Comparative analysis of ISD 598 
fragments between the reference spots and the specimen in imaging mode allows for unambiguous 599 
identification of protein markers while preserving full spatial resolution, as well as the N- and C-600 
terminal sequencing of proteins present in tissue sections. This was demonstrated with the distribution 601 
of myelin basic protein (MBP) from mouse brain and human neutrophil peptide 1 (HNP-1) in human 602 
liver sections containing metastasis from colorectal cancer. 603 
Another approach to identify proteins uses fragmentation methods in mass spectrometers applied in 604 
“top-down” protein analysis such as ETD, ECD, or UVPD172–175. These might be applicable to top-605 
down identification approaches in MSI, although the speed and sensitivity are currently not yet 606 
compatible with MSI. Even with these novel achievements, the detection of signals from intact 607 
proteins will still remain much easier than performing accurate identification, which will result in the 608 
fact that the majority of the protein signals in MSI remains unidentified. 609 
2.2 Mass spectrometry imaging of proteins after in situ digestion 610 
Another strategy used in MSI for protein imaging is in situ digestion prior to MALDI MSI analysis, 611 
which can be used to identify proteins and to determine protein distribution using surrogate 612 
proteotypic peptides. The method retrieves protein distributions in tissue sections using the 613 
corresponding proteotypic peptides after enzymatic digestion, most of the time using trypsin. 614 
Proteotypic peptides are those peptides that uniquely identify a protein and are used in bottom-up 615 
targeted and untargeted proteomics workflows to identify and quantify proteins with a (tandem) mass 616 
spectrometer176. In fact, peptides are smaller and, due to their better fragmentation, are easier to be 617 
identified by tandem mass spectrometry. Additionally, peptide fragments are easier to obtain than 618 
intact proteins from FFPE tissue. Therefore in situ digestion analysis is the method of choice for this 619 
sample type, which is more abundantly available in hospital biobanks compared to fresh frozen tissue 620 
samples. With this technique, Caprioli and coworkers described on-tissue identification of proteins 621 
in spatially discrete regions using tryptic digestion followed by MALDI MSI with (TOF-TOF) 622 
MS/MS analysis177. The procedure in this study identified several proteins in the coronal sections of 623 
a rat brain including higher molecular weight proteins, such as actin (41 kDa), tubulin (55 kDa), and 624 
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synapsin-1 (74 kDa). Ronci and Voelcker applied on-tissue trypsin digestion to analyze the freshly 625 
excised human lens capsule by MALDI MSI. This work demonstrated that the distribution of proteins 626 
can be determined from this highly compact connective tissue having no evident histo-morphological 627 
characteristics. Furthermore, the study shows a high repeatability of the digestion protocol on four 628 
different human lens capsule specimens by evaluating the distribution of the same set of peptides178. 629 
Recently, Diehl et al. optimized the in situ imaging of protein distribution after protease digestion 630 
with MALDI MSI using cryoconserved and FFPE rat brain tissue by applying different digestion 631 
times, types of matrix, and proteases179. The conclusion of this study was that the digestion time does 632 
not play an important role for the quality of MSI images, while trypsin provided the highest number 633 
of peptide signals corresponding to anatomical regions. 634 
Ion mobility separation (IMS) combined with MSI has emerged as a powerful technique to improve 635 
specific detection of isobaric peptides with different molecular shape25,180–182. For example, Clench 636 
and coworkers successfully performed IMS-MSI to localize and identify peptides of the glucose-637 
regulated protein 78 kDa (Grp78), which is known as a tumor biomarker, directly from FFPE 638 
pancreatic tumor tissue sections. Grp78 was found to be mainly located in tumor regions using 639 
MALDI-IMS-MSI181. In this procedure IMS separated isobaric peptides, which facilitated their 640 
identification following fragmentation, obtaining a cleaner image with less interferences for a 641 
particular peptide. Stauber et al. applied enzymatic digestion protocols for MALDI-IMS-MSI with 642 
high sensitivity localization and identification of proteins from FFPE and frozen tissues obtained from 643 
rat brain182. This study showed that isobaric peptides can be separated, which improves ion image 644 
specificity and improves identification accuracy of fragmented peptides. 645 
Schober et al. presented a method for imaging tryptic peptides183 in which MALDI MSI experiments 646 
were complemented by off-line liquid chromatography coupled to electrospray ionization tandem 647 
mass spectrometry (LC-ESI-MS/MS) analysis on an FT-ICR mass spectrometer to increase the 648 
number of identified peptides and proteins. Comparative results were obtained by analyzing two 649 
adjacent mouse brain sections in parallel. The first section was spotted with trypsin and analyzed by 650 
MALDI MSI. On-tissue MS/MS experiments of this section resulted in the identification of only 14 651 
peptides (originating from 4 proteins). The second tissue section was homogenized, fractionated by 652 
ultracentrifugation and digested with trypsin prior to LC-ESI-MS/MS analysis. The number of 653 
identified peptides increased to 153 (corresponding to 106 proteins) by matching imaged mass peaks 654 
to peptides which were identified in these LC/ESI-MS/MS experiments. This identification difference 655 
can be explained that selected precursor ion windows in direct fragmentation of peptides from tissue 656 
include matrix and other interference which results in noisier spectra compared to LC-MS/MS 657 
analysis where these interferences are not present. 658 
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The group of McDonnell reported a comprehensive study of the mouse brain proteome from mouse 659 
brain slices with MSI using multiple proteases such as trypsin, Lys-C, Lys-N, Arg-C, and a mixture 660 
of trypsin and Lys-C184. This study combined identification of peptides and proteins from tissue using 661 
bottom-up LC-ESI-MS/MS and linked the obtained identifications using accurate mass with non-662 
fragmented MSI data. In the LC-ESI-MS/MS data 5337 peptides were identified using 663 
complementary proteases, corresponding to 1198 proteins. 630 of these peptides, corresponding to 664 
280 proteins, could be assigned to peaks in MSI data sets and used to determine the parent protein 665 
distribution in tissue. Gene ontology and pathway analyses revealed that many of the proteins are 666 
involved in neuro-degenerative disorders, such as Alzheimer’s, Parkinson’s, and Huntington’s 667 
disease184, which highlights the potential application of the technique in the future for diagnosis and 668 
pathology purposes. 669 
Many approaches have been developed to improve protein identification performance in MALDI 670 
MSI after enzymatic digestion. For example, Franck et al. developed an N-terminal chemical 671 
derivatization strategy using 4-sulphophenyl isothiocyanate (4-SPITC), 3-sulfobenzoic acid (3-SBA) 672 
and N-succinimidyloxycarbonylmethyl-tris(2,4,6-trimethoxyphenyl)phosphonium bromide (TMPP) 673 
reagents, which improves de novo peptide identification performance185. The reagents added an 674 
additional positive or negative charge at the N-terminus of tryptic peptides, which provided more 675 
complete ion series upon fragmentation. From these reagents TMPP provided the best performance 676 
in terms of fragmentation efficiency of peptides from tissue. Clench’s group used a recombinant 677 
protein termed “IMS-TAG” for MALDI-IMS-MSI25. The IMS-TAG recombinant proteins are 678 
engineered and used as a multi-protein standard. After trypsin digestion, this IMS-TAG protein yields 679 
– analogous to the QconCAT186 approach – a range of peptides that can be used as internal standards 680 
to identify and quantify multiple proteins in a MALDI-IMS-MSI experiment. In this approach IMS 681 
is used to provide an additional selectivity to detect IMS-TAG derived standard peptides and to 682 
remove any potential interfering isobaric peptide signals. In this study, MALDI-IMS-MSI was used 683 
to measure the distribution of HSP90 and vimentin in FFPE EMT6 mouse tumor sections, as well as 684 
HSP90 and plectin in a fresh frozen mouse fibrosarcoma using extracted ion images at the 685 
corresponding m/z values and drift times from IMS-MSI data. 686 
Performing accurate protein quantification in MSI is challenging since ion suppression due to other 687 
co-localized compounds can be strong and protein extraction and desorption can be partial in case of 688 
MSI of intact proteins. Trypsin digestion may alter quantification since this step creates a new ion 689 
suppression environment. The quantification performance can be made more accurate by using spiked 690 
stable isotope standards. For example, Porta et al. used stable isotope standards and performed 691 
quantification based on fragment ions obtained in SRM mode, which allowed to achieve a 692 
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quantification precision of 10-15%, which is sufficient to meet requirements of most bioanalysis 693 
guidelines187. A further finding of this work was that single pixel quantification is less accurate and 694 
at least the average of 4-5 pixels is required for accurate quantification of compounds in MSI data. 695 
Komatsu et al. presented a feasibility study using a bismuth cluster ion (Bi3+) source with SIMS-696 
TOF-MSI to determine protein distribution at the sub-cellular level combined with the ink-jet printing 697 
of trypsin. In this approach, a modified bubble jet printer (PIXUS 990i, Canon Inc.) was used to 698 
deposit trypsin and trifluoroacetic acid on a human serum albumin film layer. Protein images were 699 
obtained by visualizing the dot-patterned proteotypic peptide ions188. Nygren and Malmberg mapped 700 
tryptic fragments of thyroglobulin (660 kDa) in pig thyroid glands after trypsin digestion by SIMS-701 
MSI using a Bi3+ primary ion source. In this study, trifluoroacetic acid in water was used to improve 702 
the ionization of the peptides, which resulted in a 3 μm spatial resolution MSI image showing a 703 
heterogeneous distribution of this protein in the thyroid follicle cells40. 704 
3 Targeted mass spectrometry imaging of protein in tissue using tag-mass 705 
probes 706 
This section presents approaches to circumvent some of the shortcomings of MALDI MSI of proteins 707 
and peptides by not using matrix and detecting proteins with targeted indirect signals resulting from 708 
chemical derivatisation and immunochemistry recognition. Two major approaches are discussed in 709 
this section: the use of LA-ICP for detecting metals in proteins and the Tag-Mass approach. 710 
LA-ICP MSI generates signals for targeted biomolecular imaging, which can be applied for MSI of 711 
proteins with high sensitivity and dynamic range, but at a relatively low spatial resolution (100-200 712 
µm). For example, Seuma et al. studied the distribution of two breast cancer-associated proteins, 713 
MUC-1 and HER2 in tissue sections by measuring Au or Ag tagged antibodies, but although 714 
successful it was concluded that the image quality was inferior to microscopy189. Becker et al. 715 
demonstrated the potential of LA-ICP-MS to detect metalloproteins in protein bands or spots excised 716 
from 1D and 2D gel electropherograms. This method was then applied for sensitive and quantitative 717 
imaging of metals in brain sections, with detection limits for copper and zinc at the μg/g tissue level 718 
and below190. Giesen et al. applied LA-ICP-MSI for imaging metal-labelled antibodies to detect and 719 
quantify proteins directly in breast cancer and palatine tonsil tissue samples191. More recently, the 720 
same group developed this method further, and used 32 metal labeled antibodies to determine 721 
simultaneously 32 markers for protein and protein modification distribution in breast cancer tissue 722 
with laser ablation on a CyTOF instrument at subcellular resolution. The subcellular resolution at 1 723 
μm enabled them to use this approach as mass spectrometry based cytometry i.e. to measure the 724 
concentration of these 32 protein markers in individual cells in tissue sections192,193. 725 
27 
In 1998, a novel PC mass tag strategy for targeted detection of proteins has been suggested by Olejnik 726 
et al.194This strategy implements the targeted analysis of proteins by affinity labeling with an antibody 727 
(or another affinity agent) containing a PC mass tag and analyzing the labeled sample with LDI. The 728 
tag contains a PC-linker, linking the antibody to the mass tag, which is cleaved upon LDI, released 729 
into the gas phase, ionized and sampled into the mass spectrometer without the requirement to apply 730 
matrix for the analysis. Due to the absence of matrix, spatial resolution is not limited by the size of 731 
the analyte-matrix co-crystal and sensitivity is improved because detection of the released mass-tag 732 
reporter fragment ion does not interfere with matrix cluster ions. In the absence of matrix, the spatial 733 
distribution of LDI image is determined by the beam diameter of the applied laser. The PC-linker is 734 
cleaved with high yield under the near-UV laser pulses commonly used in MALDI-MS instruments. 735 
With a well-designed PC-linker and mass tag, this strategy has the ability to detect non-ionizing 736 
compounds and offers high selectivity and sensitivity for target proteins. Furthermore, coupling 737 
multiple PC-linked reporter mass tags to one affinity compound enhances the sensitivity of detection 738 
by increasing the MS signal195. 739 
Although MALDI MSI has a much lower lateral resolution than classical optical microscopy (<< 1 740 
µm for example by using fluorescently labeled proteins), MS is both a sensitive method and allows 741 
for the simultaneous (mulitplexed) detection of hundreds to thousands of compounds. For 742 
fluorescence, only a restricted number of fluorophores are available, whereas the number of mass 743 
tags is only limited by the number of fragment ions that a mass analyzer can distinguish, which is a 744 
priori almost unlimited. Therefore, the mass tag method is a promising matrix-free strategy, which 745 
has a high multiplexing capacity, and the detection and localization of proteins in tissue sections with 746 
high specificity and sensitivity allowing to detect proteins larger than 30 kDa. A limitation is the 747 
availability of separate specific affinity reagents with unique mass tags for each protein to be 748 
measured and the specificity of the affinity tag. 749 
In the literature, two types of photolinkers and reporter fragments (mass tags) have been reported, 750 
which have been developed by two different research teams. The group of Fournier described a 751 
targeted PC-linker strategy termed Tag-Mass based on the photocleavable linker 4-[4-[1-(Fmoc-752 
amino)ethyl]-2-methoxy-5-nitrophenoxy]butanoic acid coupled to a peptide such as bradykinin as the 753 
mass tag. To study the possibility of using photocleavage under multiplex analysis conditions, this 754 
group used a mixture of three photocleavable-tagged oligonucleotide probes corresponding to three 755 
different 20-mer oligonucleotides recognizing particular mRNA (Figure 4)22. Although 100% 756 
photocleavage yield was not achieved using MALDI, the MS spectra showed the expected m/z of the 757 
mass tag demonstrating efficient photocleavage by laser irradiation. To increase the sensitivity, the 758 
group designed a new photocleavable linker/tag system by replacing the disulfide bridge with a 759 
28 
maleimide group for binding the peptide serving as mass tag to the photocleavable linker. This 760 
concept was applied to obtain specific images of proteins using tagged secondary antibodies. The 761 
results showed that MALDI appears to have a better sensitivity than the optical fluorescence images 762 
obtained from the same tissue section. 763 
 764 
Figure 4. Structure of a photocleavable linker/tag system conjugated to an oligonucleotide/protein moiety and the reporter 765 
mass tag released via photocleavage as a result of irradiation by the UV laser (A). MALDI spectra of the untagged 766 
proenkephalin probe (upper plot) and the Uracil-tagged (U-tagged) proenkephalin probe (B) showing the peak highlighted 767 
in red corresponding to the applied mass tag in rat brain. Ion distribution image of the mass tag corresponding to the 768 
proenkephalin mRNA distribution. Adapted with permission from Lemaire et al. 22. Copyright (2007) American Chemical 769 
Society. 770 
 771 
The Tag-Mass strategy has been extended to different types of targeting compounds including 772 
secondary and primary antibodies, lectins and aptamers, which can be used to selectively obtain 773 
images of specific protein antigens, glycosylated proteins and drugs, respectively24. It can be 774 
combined with hybridization and affinity recognition techniques including in situ hybridization of 775 
mRNA (ISH) and immunohistochemistry (IHC)22,24,196,197. 776 
In 2007, Thiery et al.198 reported a novel photocleavable mass-tag approach, where the released tag 777 
can be detected under LDI conditions and used for TAMSIM (Figure 5). TAMSIM is based on an 778 
N-hydroxysuccinimide (NHS) linker coupled to trityl reporters with a thioproprionate group, which 779 
provides low molecular weight fragments (500-600 Da) in LDI198–200. In this reagent, the trityl groups 780 
absorb UV light and form a resonance-stabilized carbocation, which results in cleavage of the C-S 781 
bond, and the release of the ionized mass-tag without the use of a matrix. This strategy was 782 
successfully applied to localize three different cancer markers on human tissue sections, 783 
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synaptophysin, protein S100 (PS100) and human melanosome (HMB45), that are normally below the 784 
detection threshold of untargeted MALDI MSI198. 785 
 786 
Figure 5. Concept of TAMSIM to measure protein spatial distributions in tissue sections with MSI using mass tag reporter 787 
ions conjugated via a photocleavable trityl group to antibodies. (A) Schematic representation of the mass-tag reporter ion 788 
released via photodissociation as a result of UV-laser irradiation upon cleavage of the trityl group coupled to the affinity 789 
tag. (B) Reaction steps of the conjugation of a mass tag reporter to an antibody via a photocleavable group and the release 790 
of the mass-tag reporter ion upon UV-laser irradiation. The photocleavable mass-tag reporter reagent contains an NHS 791 
ester as reactive group for covalent attachment to primary amino groups e.g. to the lysine residues of an antibody. In the 792 
ionization interface of the mass spectrometer the trityl groups absorb UV light resulting in the cleavage of the C-S bond 793 
and the release of the ionized mass-tag reporter ion. (C) Improved tags have the structure of alkyl or aromatic groups for 794 
mass tuning and exhibit higher stabilization of residue R on the tag. Plot (A) and (B) were adapted with permission from 795 
Thiery et al.198 and (C) with permission from Thiery et al201. Copyright (2007 and 2008) American Chemical Society. 796 
 797 
Subsequently, this approach was further improved by the same group (Figure 5C)201. In contrast to 798 
the previous version of TAMSIM, where the mass tags were coupled to secondary antibodies, the 799 
primary antibody is now directly conjugated with the affinity reagent and incubated with the tissue 800 
section. This improvement has the advantage to increase multiplexing as the approach is not limited 801 
by the number of species available for first and secondary antibody pair production. Additionally, 802 
new reporter tags were prepared, which differ from the previous tags at the level of the amide group. 803 
This new class of tags has conjugated alkynes or substituted aromatic groups, which allow for tuning 804 
the mass of the reporter tag and exhibit higher stabilization of the carbocation on the photocleavable 805 
reporter tag. These structural improvements provide more stable reagents, which facilitates handling 806 
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and sample preparation. The results showed that fewer fragments of the mass tag were observed in 807 
the gas phase, which leads to higher sensitivity. The method allowed to analyze FFPE and fresh frozen 808 
samples, with the latter having a lower number of artifact peaks in the mass spectra, as these mainly 809 
originated from paraffin in FFPE samples. This improved strategy was successfully applied to 810 
generate specific mass spectrometric images of three abundant proteins insulin, chromogranin A, and 811 
synaptophysin, and the less abundant proteins/peptides calcitonin and somastotatin localized in 812 
Langerhans islets201. 813 
Nevertheless, trityl-based PC-linkers still have several limitations. The highly hydrophobic character 814 
of the tagging reagent limits the number of PC-linker/mass tag reporters that can be conjugated to a 815 
single antibody, since it reduces the efficiency of the coupling reaction and the aqueous solubility of 816 
the resulting conjugates. To overcome this problem, Thiery et al. modified TAMSIM by using 817 
recombinant single chain variable fragments (scFv) originally designed from monoclonal IgG 818 
antibodies labeled with biotin.195 The biotinylated scFv was coupled to avidin-holding multiple PC-819 
reporter-tags to the biotin moiety to form an immune complex (IC). Essentially, the IC approach 820 
allowed the scFv to be linked to mass tags through biotin/avidin coupling and allowed to prepare the 821 
IC reagent in two steps, which was subsequently applied to the tissue section. The scFv linked to the 822 
reporter tag using this approach was used to specifically and simultaneously detect CYP1A1 and 823 
CYP1B1 in breast tumor tissue sections (Figure 6). In 2015, Lorey et al.23 presented a new signal 824 
detection method for antibody arrays using laser desorption/ionization-mass spectrometry (LDI-MS) 825 
based on small, photocleavable reporter molecules. In this work, signal amplification was achieved 826 
with a biotin labeled secondary antibody, where biotin is coupled to avidin holding several 827 
photocleavable mass-tags. Next, a highly sensitive sandwich assay is performed with immobilized 828 
primary antibody capturing prostate specific antigen (PSA) and the secondary antibody labeled with 829 
biotin/avidin/reporter-mass tag. This approach allowed to detect PSA in human plasma at clinically 830 
relevant concentrations ranging from 2 μg/mL to 200 pg/mL23. This assay has not been used for MSI 831 
yet, but it provides the option to determine the distribution of low abundant proteins in tissue sections. 832 
Yang et al.202 developed an activity-based MSI approach using reporter mass tags, which provides 833 
high spatial resolution, and high sensitivity through the use of signal amplification chemistry and high 834 
target specificity (Figure 7). In this approach, an activity-based probe (fluorophosphonate) that is 835 
specific for serine hydrolases is attached to a dendrimer through click chemistry containing more than 836 
900 reporter tags leading to a signal amplification of nearly 3 orders of magnitude. On irradiation of 837 
the labeled tissue by the laser beam in a raster pattern, the mass tags are liberated and recorded by the 838 
mass spectrometer. Consequently, the ion image of the mass tag reveals the distribution of active 839 
serine hydrolases in rat brain and mouse embryo tissue sections. Hong et al. reported a mass tag-840 
based MSI method that enables matrix-free MSI of protein biomarkers in FFPE tissues203. It involves 841 
31 
binding of the target protein with a primary antibody, followed by binding with a secondary antibody-842 
enzyme conjugate. The substrate of the enzyme coupled to the secondary antibody is then added to 843 
the tissue section, and the enzyme converts the substrate to a product, which can be detected by LDI. 844 
The product is deposited at the location of the target protein by precipitation and the precipitates (e.g. 845 
diazonium salts) serve as reporter tags detected by mass spectrometry. The enzymes horseradish 846 
peroxidase and alkaline phosphatase and various substrates have been used to demonstrate the 847 
feasibility of this novel MSI method to image protein targets in FFPE tissue samples. The spatial 848 
resolution of this is only limited by the laser spot size of the commercially available instrument 849 
reaching limit of 10 μm without overlapping laser sampling area. 850 
 851 
Figure 6. (A) Structure of the reagent used for targeted detection of reporter-tagged avidin bound to biotinylated A10B 852 
scFv on rabbit IgG coated beads used to optimize scfv-mass tag labeling. (B) Mass spectrum showing the released mass 853 
tag upon UV laser irradiation. (C-E) MS ion image of CYP1A1, CYP1B1 and both compounds on breast cancer tissue 854 
sections obtained by visualizing ion distribution of target compound specific reporter mass tag. The plot (E), which 855 
overlays the red and green colors of CYP1A1 and CYP1B1, respectively, shows that these two compounds are perfectly 856 
co-localized in the same tissue section. Adapted with permission from Thiery et al. 195. Copyright (2012) American 857 
Society for Mass Spectrometry. 858 
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 859 
Figure 7. (A) MSI strategy using an activity-based probe conjugated to a PAMAM dendrimer modified with 860 
photocleavable mass tags. Structures of (B-a) active probe, (B-b) inactive probe, and (B-c) modified PAMAM dendrimer 861 
with the photocleavable mass tag and an azide group used to couple the PAMAM dendrimer with the alkyne group of the 862 
activity probe in tissue using click chemistry. Adapted with permission from Yang et al.202. Copyright (2012) American 863 
Chemical Society. 864 
 865 
The PC-linker reporter tag strategy in MSI has significant advantages. The ability to detect a wide 866 
variety of proteins without the need of applying matrix helps to overcome previous limitations of 867 
MALDI MSI of intact proteins, i.e. low spatial resolution, restriction to the detection of high abundant 868 
and low molecular weight proteins with limited dynamic concentration range and incompatibility 869 
with FFPE tissues. The mass tag methods can be used to perform MSI on low-abundance proteins or 870 
to reveal the localization of active proteins in tissue. This approach can perform highly multiplexed 871 
analysis due to its ability to incorporate a large variety of reporter (mass) tags. However, it relies on 872 
the quality, cross-reactivity and reliability of the affinity tag (antibody, affimer or affinity probe) and 873 
provides a targeted and indirect signal of the proteins of interest, which alleviates to a certain extent 874 
the advantage of using mass spectrometry for detection. 875 
4 Conclusions and Perspectives 876 
The methods reviewed here emphasize the immense potential of MSI for studying the spatial 877 
distribution of proteins in tissue samples. Major challenges associated with sample preparation, data 878 
processing, and MS instrument design have been identified, particularly in order to simultaneously 879 
detect the distribution of large numbers of proteins with high spatial resolution and to extend the 880 
detected dynamic range with more accurate quantification. MSI of proteins is a rapidly developing 881 
field in analytical chemistry and recent developments such as novel ionization techniques, novel 882 
strategies for chemical labeling with photocleavable reporter (mass) tags, novel fragmentation 883 
approaches, and the improvements in mass spectrometry scanning speed are advancing all aspects of 884 
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this technology. For example, the mass tag-based LDI MSI approach, implemented as the Tag-Mass 885 
and TAMSIM methods, exhibits significant potential to achieve multiplexed imaging of proteins with 886 
high resolution in tissue sections with important applications in pathology laboratories as it can be 887 
used concurrent with immunohistochemistry staining. Recent advances in top-down mass 888 
spectrometry such as the enhanced transmission of high molecular mass protein ions204,205 or the 889 
introduction of novel fragmentation approaches such as UVPD, which allow more complete 890 
fragmentation of intact proteins173–175 confidently without the requirement for extensive cleanup, will 891 
further contribute to bringing protein MSI technology to maturation. Another trend holding potential 892 
improvement of protein MSI, is the combination of DESI and MALDI MSI, allowing to measure the 893 
lipid and protein distributions in subsequent analyses in the same tissue section206. In addition, MSI 894 
data can be integrated with spectroscopic images, including automatic annotation transfer of anatomic 895 
structures from microscopic images or from anatomical databases expanding the information content 896 
but also the dimensionality of the data.207–209. Combination of anatomical annotation, image fusion 897 
with bioinformatics solutions enabling to process and evaluate the large volume of MSI data in 898 
interactive way without loss of information would further improve the information that can be 899 
obtained from MSI studies. 900 
All these technological advances will contribute to the full development of the MSI technology to 901 
profile protein distributions in tissues and will allow to broaden its scope in various fundamental and 902 
clinical applications, including new ways of pathological evaluation of tissue biopsies taken from 903 
patients to support diagnostics. 904 
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